Takeda Pharmaceutical Company Limited
Bispecific antibodies against plasma kallikrein and Factor XII

Last updated:

Abstract:

Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.

Status:
Grant
Type:

Utility

Filling date:

31 Dec 2015

Issue date:

19 Jul 2022